zacks.com
PEN Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise
Penumbra jumps after Q4 earnings and revenue beat, with double-digit sales growth, margin expansion and strong U.S. performance across key product lines.
Penumbra, Inc.PENNYSE
Loading
Latest News
defenseworld.net
Artisan Partners Limited Partnership Raises Position in Penumbra, Inc. $PEN
Artisan Partners Limited Partnership increased its holdings in Penumbra, Inc. (NYSE: PEN) by 9.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 223,476 shares of the company's stock after purchasing an additional 19,418 shares during the period.
zacks.com
Compared to Estimates, Penumbra (PEN) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Penumbra (PEN) Surpasses Q4 Earnings and Revenue Estimates
Penumbra (PEN) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $0.97 per share a year ago.
prnewswire.com
Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025.
zacks.com
CLPBY or PEN: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Instruments stocks have likely encountered both Coloplast A/S Sponsored ADR (CLPBY) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
prnewswire.com
Boston Scientific announces results for fourth quarter and full year 2025
MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period.
zacks.com
GMED vs. PEN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks is more attractive to value investors?
prnewswire.com
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
defenseworld.net
Hussman Strategic Advisors Inc. Makes New Investment in Penumbra, Inc. $PEN
Hussman Strategic Advisors Inc. acquired a new stake in Penumbra, Inc. (NYSE: PEN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 12,600 shares of the company's stock, valued at approximately $3,192,000. Penumbra makes up 0.7% of Hussman Strategic Advisors Inc.'s holdings,
globenewswire.com
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights
seekingalpha.com
Artisan Small Cap Fund Q4 2025 Portfolio Activity
During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investment campaigns in Integer Holdings and SharkNinja during the quarter.
prnewswire.com
Halper Sadeh LLC Encourages PEN, FONR, GDOT Shareholders to Contact the Firm to Discuss Their Rights
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
globenewswire.com
Halper Sadeh LLC Encourages PEN, CVGW, AVO Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Penumbra, Inc.
prnewswire.com
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN
NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
zacks.com
Penumbra (PEN) Moves 11.8% Higher: Will This Strength Last?
Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
gurufocus.com
Market Today: TSMC beat, Goldman soars, Spotify hikes
Stock News Verizon issues credits after outage: Verizon (VZ) said it resolved a nationwide wireless outage and will offer a $20 account credit to affected custo
prnewswire.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Penumbra, Inc. (NYSE: PEN)
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Penumbra, Inc. (NYSE: PEN) related to its sale to Boston Scientific Corporation.
gurufocus.com
Boston Scientific's $14.5B Acquisition of Penumbra Raises Investor Concerns
Boston Scientific (BSX) is experiencing a significant drop in its stock price after announcing its plan to acquire Penumbra (PEN) in a deal worth approximately
proactiveinvestors.com
Boston Scientific to acquire Penumbra in $14.5B deal
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) announced a definitive agreement to acquire medical device company Penumbra (NYSE:PEN) in a cash and stock transaction valuing Penumbra at $374 per share, or approximately $14.5 billion in enterprise value. Penumbra shares rose almost 12% on the news to about $350, while Boston Scientific shares fell 4.5% to about $90.